Neurobehavioral Disorders
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Neurobehavioral Disorders
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Multiple Sclerosis
A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
Neurobehavioral Disorders
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
Neurobehavioral Disorders
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
Neurobehavioral Disorders
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
Neurobehavioral Disorders
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
Neurobehavioral Disorders
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.
Neurobehavioral Disorders
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
Neurobehavioral Disorders
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
